Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine for Advanced Salivary Cancer
NCT00003744Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 1998
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in salivary gland cancer (SGC), sponsored by Dana-Farber Cancer Institute. Started Nov 1998; status: completed.
02
Drugs
gemcitabine
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT00003744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003744.